Lisa Salvatore

Università Cattolica del Sacro Cuore — Italy

Medicine · Health Sciences

41h-index7.7kcitations480works2.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Colorectal Cancer Treatments and Studies(287), Cancer Treatment and Pharmacology(100), Gastric Cancer Management and Outcomes(92), Genetic factors in colorectal cancer(81), Cancer Immunotherapy and Biomarkers(67)

Publications480 total

Switch from cetuximab to panitumumab during encorafenib-based therapy in BRAF V600E mutated metastatic colorectal cancer: An international multicenter analysis from the AGEO group
Clinics and Research in Hepatology and Gastroenterology·2025Open Access
Germline pathogenic variants identification through Comprehensive Cancer Genome Profiling
2025Open Access
Clinicomics for Predicting HER2 Expression in Metastatic Colorectal Cancer: A Multicenter Machine Learning Analysis on Real-World Data
Oncology·2025
A phase III randomized clinical trial of Gemcitabine and Nab-Paclitaxel as switch maintenance versus continuation of modified FOLFIRINOX as first-line chemotherapy in patients with advanced pancreatic cancer: The PANThEON Study
Digestive and Liver Disease·2025
Supplementary Figure S1 from An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer
2025Open Access
Supplementary Figure S3 from An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer
2025Open Access
Supplementary Figure S2 from An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer
2025Open Access
Supplementary Table S1 from An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer
2025Open Access
Long-term survival and prognostic factors after repeated metastasectomies in metastatic colorectal cancer: a 15-years retrospective study
The Oncologist·2025Open Access
Prognostic impact of Geriatric 8 and comprehensive geriatric assessment in older patients with advanced pancreatic ductal adenocarcinoma
Journal of Geriatric Oncology·2025· 2 citedOpen Access
Impact of Human Epidermal Growth Factor Receptor 2 in Patients With Metastatic Colorectal Cancer Treated With Chemotherapy Plus Bevacizumab or Anti-EGFRs: Exploratory Analysis of Eight Randomized Trials
Journal of Clinical Oncology·2025· 7 citedOpen Access
880eP Conversion therapy with encorafenib + cetuximab (EC) for chemo-refractory BRAF V600E-mutated oligometastatic colorectal cancer (OM-CRC): A tertiary center experience
Annals of Oncology·2025
3064eP Age-related genomic differences in solid tumors: A pan-cancer analysis of young and elderly patients from the FPG500 Project
Annals of Oncology·2025
745P Estimating the clinical benefit of the secondary resection of metastases in liver-limited metastatic colorectal cancer: An individual patient data-based pooled analysis of nine randomized trials
Annals of Oncology·2025
90P Double genomic alterations in patients with advanced biliary tract cancer: Clinical, pathological and survival data from an Italian and Spanish dataset
Annals of Oncology·2025
3154P Germline pathogenic variants identified through a comprehensive cancer genome profiling program
Annals of Oncology·2025
743P Combined analysis of overall survival (OS) from the phase III CodeBreaK 300 and phase Ib CodeBreaK 101 studies of sotorasib 960 mg plus panitumumab (soto960+pani) therapy for chemorefractory KRAS G12C-mutated metastatic colorectal cancer (mCRC)
Annals of Oncology·2025
First-line PD-1 +/- CTLA-4 blockade in patients with deficient mismatch repair and/or microsatellite instability-high metastatic colorectal cancer
The Oncologist·2025· 2 citedOpen Access
Health-related quality of life in patients with KRASG12C-mutated chemorefractory metastatic colorectal cancer treated with sotorasib plus panitumumab or standard of care (CodeBreaK 300): results from a phase 3, randomised clinical trial
The Lancet Oncology·2025· 4 citedOpen Access
Fertility and sexuality in early-onset colorectal cancer patients: a monocentric survey
ESMO Gastrointestinal Oncology·2025Open Access
page 1 of 24Next →

Frequent Co-authors

Chiara Cremolini(38), Alfredo Falcone(34), Fotios Loupakis(33), Gianluca Masi(26), Sara Lonardi(20), Marta Schirripa(17), Carlotta Antoniotti(16), Gabriella Fontanini(13), Francesca Bergamo(13), Giuseppe Tonini(12), Luca Boni(12), Filippo Pietrantonio(12), Federica Marmorino(12), Giuseppe Aprile(12), Daniele Santini(9), Giampaolo Tortora(9), Vittorina Zagonel(8), Monica Ronzoni(8), Bruno Vincenzi(8), Francesco Graziano(8)